Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG

Lymphoma

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Leuk Lymphoma

Phillips T, Zhou Z, Gutierrez C, Shao A, Boyd M, Noshad S, Hohlbauch A, Liu N, Repetny K, Fanale M, Mitchell B, Davis EA, Gennarelli R, Burke JM

doi: 10.1080/10428194.2025.2604300

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Non-Malignant Blood Disorders

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

Am J Hematol

Röth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, Gustovic P, Nishimura JI, Brodsky RA

doi: 10.1002/ajh.70268

Myeloproliferative Neoplasms (MPNs)

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

Leuk Lymphoma

Kuykendall AT, Palandri F, Fillbrunn M, Liu T, Zhang S, Zhang A, Simpson R, Sajeev G, Signorovitch J, Patnaik D, Gerds AT

doi: 10.1080/10428194.2026.2628361

Lung, Respiratory and Thoracic Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

Int J Cancer

Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R

doi: 10.1002/ijc.70203

Skin Cancer

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Eur J Cancer

Albrecht LJ, Garnier J, Zaremba A, Brauch L, Brunnert F, Rauschenberg R, Forschner A, Vazquez XG, Mangana J, Erdmann M, Angela Y, Franklin C, Tietze J, Lodde G, Tasdogan A, Seier JA, Roesch A, Ugurel S, Berking C, Gutzmer R, Heinzerling L, Meier F, Mohr P, Hassel JC, Schadendorf D, Livingstone E, Zimmer L

doi: 10.1016/j.ejca.2026.116595

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Related content

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States